Platform Technology Company Customers Resources Support WORKFLOW Antibody Discovery Lead molecules against any target. At record pace. CUSTOMER WEBINARS Workflow in action See how our customers apply our antibody discovery workflow to solve real world problems. FEATURED: Abveris on “Lessons Learned from 2+ Years of Discovering Functional Antibodies on the Beacon” WATCH MORE: Vanderbilt University on finding SARS-CoV-2 antibodies ChemPartner on finding antibodies against membrane targets Genovac on difficult targets Target to lead molecule in weeks, not months. The Opto™ Plasma B Discovery workflow on the automated Beacon® system enables high-resolution screening of plasma B cells with unprecedented speed. Directly clone B cells from multiple compartments Generate diverse hit panels Downselect lead candidates with functional characterization Recover re-expressed lead molecules in just 1 week Accelerate the time to clinic to realize millions in enabled revenue RAPIDLY DOWNSELECT LEAD MOLECULES AND PREPARE LIBRARIES FOR NGS SEQUENCING ABVERIS Tracey Mullen, MBA, CEO The ability to both multiplex and run sequential assays increases the screening resolution beyond what is possible in alternative single cell discovery platforms, making the Beacon in our opinion one of the most powerful high content screening tools in the industry. Guaranteed campaign success. Find antibodies against any target by putting function first and accessing broad B cell diversity. MEMBRANE TARGETS Direct functional profiling of B cells enables discovery of 10-fold more antibodies against GPCRs and other high-value targets. See the customer case study © Genovac Antibody Discovery LLC. All rights reserved. RARE MOLECULES Access to different species and B cell compartments to screen greater biodiversity. Read the application note HIGH POTENCY ANTIBODIES Screening throughput of up to 100,000 B cells from a single sample allows recovery of higher affinity antibodies. Review customer case studies CASE STUDY: FROM DONOR TO LEAD ANTIBODY IN 18 DAYS Get to the clinic faster. The Opto Plasma B Discovery workflow enables cloning and direct functional profiling of B cells in a single day. Vanderbilt University delivered sequences of confirmed SARS-CoV-2 neutralizing antibodies to downstream manufacturing partners in just 18 days using this workflow. Two of these antibodies form the basis of an AstraZeneca antibody cocktail for the treatment of COVID-19 currently in Phase III clinical trials. These significant time savings not only enable a rapid response to emerging pandemics but can also deliver millions of dollars in enabled revenue and return on investment. Learn more about Vanderbilt’s antibodies Leave no hit behind. Have high hit rates? No problem! Recover every one with OptoSeq Barcoded BCR. Screen up to 50,000 plasma B cells and recover 1000s of hits from a single automated 4-chip workflow Run multiple workflows to screen up to 100,000 cells from a single sample to recover >10,000 hits Recover antibody sequences with high-efficiency using OptoSeq Barcoded BCR Link sequence to functional profiles OptoSeq™ Barcoded BCR enables linkage of sequence to function by dual optical and genetic barcoding. Fluorescence signatures of beads are decoded on the Beacon system prior to exporting into specific locations in well plates. The genetic barcodes read by NGS sequencing can then be mapped to each bead, linking every antibody sequence to its corresponding function. Recover lead molecules, not just sequences. Re-express >1,000 antibodies in 1 week without gene synthesis and cloning. The Opto BCR Rapid Re-expression kit converts antibody sequences into molecules in just 1 week for plate-based confirmation assays. Amplified cDNA is cloned into expression constructs in one step, enabling expression of >1,000 antibodies for rapid functional confirmation. Related Resources View All Antibody Discovery Resources Antibody Discovery Brochure: Lead Molecules Against Any Target. At Record Pace. Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets. Antibody Discovery Brochure: Get to the Clinic First with Best-In-Class Antibody Therapeutics Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics. Antibody Discovery Webinar: A Beacon for Rapid Antibody Discovery against Difficult Targets Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species. Ready to discuss access options? Ask us about purchase options including our new TechAccess Subscription.* *Available in select regions Learn More Platform Company Customers Careers Resources Support Get In Touch General Inquiries info@berkeleylights.com +1 (510) 858-2855 Tech Support techsupport@berkeleylights.com +1 (888) 254-5595 / Ext. 4 Subscribe to our quarterly newsletter, BLI News. Check out our current issue © 2021 Berkeley Lights. All Rights Reserved. Site by Metropolis. Privacy Policy Terms of Use Patents